Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory re...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristina, Valerie, Herrera-Gómez, Ruth Gabriela, Szturz, Petr, Espeli, Vittoria, Siano, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862353/
https://www.ncbi.nlm.nih.gov/pubmed/31671550
http://dx.doi.org/10.3390/ijms20215399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862353/
https://www.ncbi.nlm.nih.gov/pubmed/31671550
http://dx.doi.org/10.3390/ijms20215399

Ejemplares similares